{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:09:05Z","timestamp":1760148545820,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit more than 200 countries with more than 750 million confirmed cases and more than 6 million deaths worldwide [...]<\/jats:p>","DOI":"10.3390\/jcm12103386","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T04:26:29Z","timestamp":1683692789000},"page":"3386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing an \u2018Old\u2019 Drug for the Treatment of COVID-19-Related Cytokine Storm"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-0442","authenticated-orcid":false,"given":"Emanuele","family":"Pontali","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Galliera Hospital, 16128 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Filauro","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Galliera Hospital, 16128 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","unstructured":"WHO (2023, March 05). Coronavirus Disease (COVID-19) Pandemic. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"L115","DOI":"10.1152\/ajplung.00126.2020","article-title":"Thoughts on the alveolar phase of COVID-19","volume":"319","author":"Mason","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13054-021-03513-9","article-title":"Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS","volume":"25","author":"Jouan","year":"2021","journal-title":"Crit. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13054-020-03427-y","article-title":"Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS","volume":"25","author":"Bendib","year":"2021","journal-title":"Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2020.17052","article-title":"Cytokine Levels in Critically Ill Patients with COVID-19 and Other Conditions","volume":"324","author":"Kox","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Atluri, K., Aimlin, I., and Arora, S. (2022). Current Effective Therapeutics in Management of COVID-19. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133838"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/art.41422","article-title":"Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series","volume":"72","author":"Sattui","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study","volume":"147","author":"Bozzi","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia","volume":"147","author":"Pontali","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s13054-020-03364-w","article-title":"RCI-COVID-19 Study Group. Anakinra treatment in critically ill COVID-19 patients: A prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"eLife"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bodro, M., Cofan, F., R\u00edos, J., Herrera, S., Linares, L., Marcos, M.A., Soriano, A., Moreno, A., and Diekmann, F. (2021). Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081551"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ursino, M., Dupuis, C., Buetti, N., de Montmollin, E., Bouadma, L., Golgran-Toledano, D., Ruckly, S., Neuville, M., Cohen, Y., and Mourvillier, B. (2021). Multistate Modeling of COVID-19 Patients Using a Large Multicentric Prospective Cohort of Critically Ill Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030544"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Garc\u00eda, J.A., P\u00e9rez-Quintana, M., Ramos-Gir\u00e1ldez, C., Cebri\u00e1n-Gonz\u00e1lez, I., Mart\u00edn-Ponce, M.L., Del Valle-Villagr\u00e1n, J., Navarro-Puerto, M.A., S\u00e1nchez-Villegas, J., G\u00f3mez-Herreros, R., and Manoja-Bustos, I. (2021). Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. J. Clin. Med., 10.","DOI":"10.3390\/jcm10174019"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kyriakoulis, K.G., Kollias, A., Poulakou, G., Kyriakoulis, I.G., Trontzas, I.P., Charpidou, A., and Syrigos, K. (2021). The Effect of Anakinra in Hospitalized Patients with COVID-19: An Updated Systematic Review and Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194462"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Marc, F., Moldovan, C.M., Hoza, A., Magheru, S., Ciavoi, G., Farcas, D.M., Sachelarie, L., Calin, G., Romila, L., and Damir, D. (2022). Comparative Study of Cytokine Storm Treatment in Patients with COVID-19 Pneumonia Using Immunomodulators. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102945"},{"key":"ref_28","unstructured":"The REMAP-CAP Investigators (2021). Effectiveness of Tocilizumab, Sarilumab, and Anakinra for Critically Ill Patients with COVID-19 the REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial, Cold Spring Harbor Laboratory."},{"key":"ref_29","unstructured":"RIMUNO-19 Collaborative Group (2021). Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): A randomised controlled trial. Lancet Respir. Med., 9, 295\u2013304."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:31:59Z","timestamp":1760124719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103386"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103386","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}